Your wrong- the Philippines already could have done exactly what your stating give EUA to a drug that got it in US for example they have loosened restrictions for their own health department to make their own EUA. Also CYDY has a insider support much to the likes of how Gilead in the US. It’s a bonus either way the open label is a bonus phillipines is bonus, etc HIV approval is going to happen soon prob mid 2021 or sooner and SP from that alone along with all other possible indications should be $30+ You add covid-19 EUA-Approval as best mortality reduction drug in middle of pandemic and sky is limit $50+ $80+ Is in the realms of what we could see especially if moved to nasdaq after an approval announcement or a sale locked up. Most longs will not sell any shares until we hit those targets way way to much upside. Shorts don’t realize that when they try scare investors that they would have to scare them out of 20+ indications because at price we’re at now $5 1 approval of 25+ chances and were 5x 8x 20x our current price. Nice knowing you shorts some you won’t have any say when forced to exit positions, others will make decision on your own, some might even join the other side the smart ones that have figured out they will make multiples more actually buying and holding.